Studying resistance to antibody-drug conjugates in advanced cancer
Part of Cancer clinical trials.
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced cancer (breast, bladder, lung, or stomach) that cannot be removed by surgery, and you are about to start treatment with an antibody-drug conjugate (ADC).
- You must have at least two tumor sites (not in bone or brain) that can be measured and one that can be safely biopsied.
- You are willing to have two tumor biopsies (one before treatment and one during) and provide blood samples for research.
- You are generally well enough to be up and about (ECOG performance status 0, 1, or 2).
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This study tests whether a personalized dietary plan can help manage side effects and improve well-being in women with advanced breast or gynecologic cancer who are receiving antibody-drug conjugate (ADC) therapy. ADCs are a type of targeted cancer treatment that delivers chemotherapy directly to cancer cells.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This study tests a new type of targeted therapy called an antibody-drug conjugate (ADC) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people whose cancer has progressed after CDK4/6 inhibitor treatment, and may offer a new option to slow tumor growth.
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.